SAN JOSE, Costa Rica, Nov. 14, 2007 (PRIME NEWSWIRE) -- DNA Dynamics, Inc. (Pink Sheets:DNAD) (www.ddnnaa.com) is proud to be amongst the few USA publicly traded companies attending Bio-Europe, an industry-leading Biotechnology/Pharmaceutical conference held in Hamburg, Germany. Slated as the premier conference to forge new business and relationships in the biotechnology & pharmaceutical sector, DNA Dynamics Inc. has pre-scheduled meetings with 22 biotech/pharma companies for possible advancement of strategic alliances.
"New revenue sources as well as long term relationships with new DNA driven technology companies, including sponsorships are all points of interest with DNA Dynamics," stated DNAD President Roman Romaniuk. "Our future growth of the company has unlimited potential when you apply the myriad of DNA driven technologies that are being researched and discovered today. Many of these new discoveries are being represented here at Bio-Europe."
From obesity and weight loss to cancer to individual human DNA specific medications, these are all areas with significant DNA driven technologies being researched and developed throughout the world. DNA Dynamics Inc. plans to provide value to our shareholders through participation in these types of exciting developments.
ABOUT DNA DYNAMICS
The company assists in exposing and developing new DNA driven technologies. Many of these DNA driven technologies can be used as a basis for a range of developmental opportunities using clinical and/or genomic data as well as targeting demographic health trends like obesity. The company's business is focused on task-related Research & Development for larger Biotech organizations and providing finance, sponsorships and exposure to small to medium sized biotech organizations with DNA driven technologies.
FOR FURTHER INFORMATION & DISCUSSION
Investors are invited to visit the DNA Dynamics Inc. IR Hub at AGORACOM: http://www.agoracom.com/ir/DNA, where they can post questions and receive answers or review questions and answers already posted by other investors. Alternatively, investors are able to e-mail all questions and correspondence to mailto: DNA@agoracom.com where they can also request to be added to the investor e-mail list to receive all future press releases and updates in real time.
ABOUT BIO-EUROPE
BIO-Europe brings together international decision-makers from the biotechnology, pharmaceutical and financial sectors, offering networking opportunities, workshop participation, and private, prescheduled one-to-one meetings. Investment and collaboration opportunities developed in prior BIO-Europe conferences have produced many highly successful business partnerships. In addition, high level faculty will participate in panels and workshops. They include renowned industry experts who provide updated analyses as well as seasoned professionals who share their experience with the audience. Topics chosen reflect the most important issues affecting the life science industry today. Topics cover partnering, finance and other issues of importance to the biotech industry.
Legal Notice Regarding Forward-Looking Statements
No statement herein should be considered an offer or a solicitation of an offer for the purchase or sale of any securities. This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although the Company believes that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, it can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements, which involve assumptions and describe our future plans, strategies, and expectations, are generally identifiable by use of the words "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties, including but not limited to adverse economic conditions, intense competition, lack of meaningful research results, entry of new competitors and products, adverse federal, state and local government regulation, inadequate capital, unexpected costs and operating deficits, increases in general and administrative costs, termination of contracts or agreements, technological obsolescence of the Company's products, technical problems with the Company's research and products, price increases for supplies and components, litigation and administrative proceedings involving the Company, the possible acquisition of new businesses or technologies that result in operating losses or that do not perform as anticipated, unanticipated losses, the possible fluctuation and volatility of the Company's operating results, financial condition and stock price, losses incurred in litigating and settling cases, dilution in the Company's ownership of its business, adverse publicity and news coverage, inability to carry out research, development and commercialization plans, loss or retirement of key executives and research scientists, changes in interest rates, inflationary factors, and other specific risks. The Company undertakes no obligation to publicly release the results of any revisions to these forward looking statements that may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.